Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 6Glioblastoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Phase IB 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Mesonephric Gynecologic Cancer 1Melanoma 1Lung Neoplasms 1Low-Grade Serous Ovarian Cancer 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Brain Neoplasms 1Advanced Colorectal Cancer 1Adenocarcinoma of Lung 1

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms × defactinib × Clear all
NCT03287271 2024-08-12

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

University of California, San Diego

Phase 1/2 Recruiting
90 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡